Jan 28 (Reuters) - Regenxbio said on Wednesday the U.S. Food and Drug Administration has placed a clinical hold on two of its ...

A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...

A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.

The FDA, on Wednesday, unexpectedly placed two of Regenxbio's experimental gene therapies on hold after a patient developed a ...

Shares of Regenxbio plunged after the Food and Drug Administration placed clinical holds on two drug development programs after a five-year-old participant in one study developed an intraventricular ...

The discovery of a tumor in a patient who received REGENXBIO’s gene therapy for Hurler syndrome prompted the FDA to place a hold on that program along with the company’s Hunter syndrome program, which ...

The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...

The Food and Drug Administration paused trials for two experimental gene therapies from Regenxbio after one child developed a ...

REGENXBIO shares sink after the FDA places a clinical hold on two gene therapy trials following a safety concern tied to ...

Regenxbio Inc. faces pivotal catalysts in 2026, notably RGX-121's FDA decision and RGX-202 Duchenne data, potentially ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its ...

Investing.com -- REGENXBIO Inc. (NASDAQ:RGNX) stock fell 28% Wednesday after the FDA placed clinical holds on two of its ...